Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Published:2010-01 Issue:1 Volume:116 Page:15-20
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Fleming Gini F.,Sill Michael W.,Darcy Kathleen M.,McMeekin D. Scott,Thigpen J. Tate,Adler Lisa M.,Berek Jonathan S.,Chapman Julia A.,DiSilvestro Paul A.,Horowitz Ira R.,Fiorica James V.

Funder

Genentech

National Cancer Institute

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference25 articles.

1. Trastuzumab—mechanism of action and use in clinical practice;Hudis;N. Engl. J. Med.,2007

2. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients;Morrison;J. Clin. Oncol.,2006

3. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization,HER-2/neu, p53 and Ki-67 protein expression, and outcome;Peirâo;Mod. Pathol.,2004

4. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study;Grushko;Gynecol. Oncol.,2008

5. Optimal flexible designs in phase II clinical trials;Chen;Stat. Med.,1998

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of ERBB2-Low Expression in Endometrial Cancer;JAMA Oncology;2024-09-05

2. High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options;Reproductive Sciences;2024-04-24

3. Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma;Applied Immunohistochemistry & Molecular Morphology;2024-04-18

4. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls;Histopathology;2024-03-05

5. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2);Gynecologic Oncology;2024-03